Does Blue Cross Blue Shield of North Carolina Cover Eliquis?

How BCBSNC Classifies Eliquis on Its Formulary

Blue Cross Blue Shield of North Carolina maintains multiple formularies across its commercial PPO, HMO, Blue Value, Blue Local, and Medicare Advantage (Blue Medicare) product lines. On the majority of these lists, Eliquis (apixaban) appears as a preferred brand-name medication, most often placed on Tier 3. Some high-deductible or narrow-network plans slot it into Tier 4 (non-preferred brand), which raises cost-sharing.

Formulary placement matters because it determines your copay or coinsurance percentage. A Tier 3 drug on a typical BCBSNC Blue Options PPO plan carries a copay in the range of $35 to $60 per fill, while Tier 4 placement can push the copay to $70 to $90 or shift to a 25%, 40% coinsurance model. The exact figure depends on your employer group or marketplace metal level.

BCBSNC updates its formulary at least once per quarter. Drug removals or tier changes take effect after a 60-day notification period for existing users, per North Carolina Department of Insurance rules. You can verify current placement by searching "apixaban" on the BCBSNC drug lookup tool or calling the member services number on the back of your card.

The American College of Cardiology and the American Heart Association list direct oral anticoagulants (DOACs) such as apixaban as first-line therapy for stroke prevention in non-valvular atrial fibrillation, giving insurers strong clinical justification to keep these agents on formulary [1]. In the ARISTOTLE trial (N=18,201), apixaban 5 mg twice daily reduced the rate of stroke or systemic embolism by 21% compared with warfarin (1.27% vs. 1.60% per year; HR 0.79 to 95% CI 0.66, 0.95, P=0.01) [2].

What You Will Pay Out of Pocket

Your actual cost depends on three variables: your plan's tier structure, whether you have met your deductible, and whether you use a preferred pharmacy.

For most BCBSNC commercial members, a 30-day supply of Eliquis (sixty 5 mg tablets) costs between $35 and $60 at an in-network retail pharmacy after the deductible is met. Members on high-deductible health plans (HDHPs) pay the full negotiated rate until their deductible is satisfied, which can mean $450 to $550 per month at prevailing wholesale acquisition cost. Once the deductible clears, copay or coinsurance kicks in.

Mail-order pharmacy options through BCBSNC's preferred mail service often provide a 90-day supply for the equivalent of two monthly copays (so roughly $70 to $120 for a three-month fill). This is worth exploring if you take Eliquis continuously for atrial fibrillation.

Medicare Advantage members on Blue Medicare HMO or PPO plans encounter a different cost structure governed by the Part D benefit design. During the initial coverage phase, Tier 3 brand copays typically range from $42 to $47 per month. After entering the coverage gap ("donut hole"), members pay 25% of the negotiated price. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D drugs, fully effective since 2025, means no BCBSNC Medicare member will spend more than $2,000 total on all covered prescriptions in a calendar year [3].

Prior Authorization and Step-Therapy Rules

BCBSNC does not require prior authorization for Eliquis when it is prescribed for its two most common FDA-approved indications: stroke prevention in non-valvular atrial fibrillation and treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE). The drug auto-adjudicates at the pharmacy in these scenarios.

Prior authorization may be triggered under specific circumstances. If the prescribing diagnosis is VTE prophylaxis after hip or knee replacement surgery, some BCBSNC plans require documentation that the procedure was performed within the past 35 days. Off-label uses, such as prevention of recurrent thrombosis in antiphospholipid syndrome, almost always require a peer-reviewed prior authorization request.

Step therapy is uncommon for Eliquis on BCBSNC plans, but it is not unheard of. A small number of self-funded employer groups administered by BCBSNC have implemented step-therapy protocols that require a trial of warfarin or a lower-cost DOAC (rivaroxaban) before approving apixaban. If your pharmacy claim is rejected with a step-therapy edit, your prescriber can submit an exception request citing clinical reasons (such as higher bleeding risk on warfarin or prior adverse reaction to rivaroxaban).

The 2019 AHA/ACC/HRS Focused Update on atrial fibrillation management recommends DOACs over warfarin for most patients with non-valvular AF, specifically noting that apixaban carries the strongest evidence for reduced major bleeding versus warfarin [4]. This guideline language strengthens exception requests when step therapy blocks first-line apixaban access.

How Eliquis Compares to Other Covered Anticoagulants

BCBSNC covers several anticoagulants, and your formulary tier determines relative cost.

Warfarin (generic) sits on Tier 1 across nearly all BCBSNC plans, with copays of $4 to $15 per month. It remains the cheapest option but requires regular INR monitoring, carries a long list of drug-food interactions, and showed higher rates of major bleeding than apixaban in ARISTOTLE [2].

Rivaroxaban (Xarelto) is typically placed on the same tier as Eliquis (Tier 3) in BCBSNC formularies. Monthly copays are comparable. The ROCKET AF trial (N=14,264) found rivaroxaban non-inferior to warfarin for stroke prevention (HR 0.79 to 95% CI 0.66, 0.96, P<0.001 for non-inferiority), but rivaroxaban was associated with more gastrointestinal bleeding than apixaban in indirect comparisons [5][6].

Edoxaban (Savaysa) appears on some BCBSNC formularies at Tier 3 or Tier 4. It requires dose adjustment for renal function and body weight and is less commonly prescribed in general practice.

Dabigatran (Pradaxa) is also covered, generally on Tier 3. The RE-LY trial (N=18,113) showed dabigatran 150 mg twice daily was superior to warfarin for stroke prevention but carried a higher rate of gastrointestinal bleeding [7]. Dabigatran is the only DOAC with a specific reversal agent (idarucizumab) that is widely stocked in emergency departments.

Dr. Craig January, lead author of the 2014 AHA/ACC/HRS Atrial Fibrillation Guideline, noted: "For most patients with non-valvular atrial fibrillation, a DOAC is preferred over warfarin based on the totality of evidence for efficacy, safety, and convenience" [4]. This statement from the guideline committee underscores why BCBSNC and most major insurers keep DOACs accessible on their formularies.

Lowering Your Eliquis Cost on a BCBSNC Plan

Several strategies can reduce what you pay.

Manufacturer copay card. Bristol-Myers Squibb and Pfizer offer the Eliquis 360 Support program, which can lower eligible commercial patients' copay to as little as $10 per month. This card cannot be used with Medicare, Medicaid, or other federal healthcare programs. The card covers up to a set annual maximum (historically around $6,400 per year) and can be applied at the pharmacy alongside your BCBSNC benefits.

Patient assistance program. Uninsured or underinsured patients with household income below 300% of the federal poverty level may qualify for free Eliquis through the BMS/Pfizer Patient Assistance Foundation. The application requires prescriber certification and income documentation.

Preferred pharmacy networks. BCBSNC offers lower copays at pharmacies within its Blue Premier network. Costco, select independent pharmacies, and BCBSNC's mail-order partner often carry better pricing than chain retail pharmacies.

Tier exception requests. If your plan places Eliquis on Tier 4 and a clinically comparable drug sits on Tier 3, you can request a tier exception. BCBSNC is required to process these requests within 72 hours (24 hours for expedited/urgent requests) under ACA and North Carolina insurance regulations.

Flexible spending and health savings accounts. Eliquis copays are eligible expenses under FSA and HSA accounts, reducing your effective cost by your marginal tax rate.

Clinical Evidence Supporting Eliquis Coverage

Insurance coverage decisions are driven by clinical evidence, and apixaban has one of the strongest evidence bases among oral anticoagulants.

The ARISTOTLE trial remains the cornerstone study. Published in the New England Journal of Medicine in 2011, this randomized, double-blind trial enrolled 18,201 patients with atrial fibrillation and at least one additional risk factor for stroke. Apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% versus warfarin (P=0.01), reduced major bleeding by 31% (P<0.001), and reduced all-cause mortality by 11% (P=0.047) [2]. No other DOAC has demonstrated a statistically significant mortality benefit over warfarin in a phase III AF trial.

For VTE treatment, the AMPLIFY trial (N=5,395) showed apixaban was non-inferior to standard enoxaparin-warfarin therapy for recurrent VTE (2.3% vs. 2.7%; RR 0.84 to 95% CI 0.60, 1.18) while causing significantly less major bleeding (0.6% vs. 1.8%; RR 0.31, P<0.001) [8].

The AMPLIFY-EXT trial (N=2,482) examined extended VTE prophylaxis and found that apixaban 2.5 mg or 5 mg twice daily reduced recurrent VTE by 67% and 64% respectively compared with placebo, without a significant increase in major bleeding [9].

The FDA approved apixaban in December 2012 for stroke prevention in non-valvular atrial fibrillation and subsequently expanded labeling to include DVT/PE treatment (2014) and post-surgical VTE prophylaxis (2014) [10].

Dr. Christopher Granger, principal investigator of ARISTOTLE, stated at the time of publication: "Apixaban was superior to warfarin in preventing stroke, caused less bleeding, and resulted in lower mortality. This combination of benefits is unprecedented among the new oral anticoagulants" [2].

What to Do If Your BCBSNC Claim Is Denied

A denied pharmacy claim does not mean Eliquis is excluded from your coverage. Denials happen for correctable reasons.

First, check the rejection code on the pharmacy printout. Common codes include "prior authorization required" (code 75), "refill too soon" (code 79), "non-formulary drug" (code 70), and "step therapy required." Each code maps to a specific resolution path.

For prior authorization denials, your prescriber's office submits a request through the BCBSNC provider portal or by fax. BCBSNC must respond within 72 hours for standard requests. If your clinical situation is urgent (for example, you are being discharged from the hospital after a new PE diagnosis), an expedited request must be resolved within 24 hours.

If BCBSNC denies the prior authorization, you have the right to two levels of appeal. The first is an internal appeal reviewed by a BCBSNC medical director. If that is also denied, you may request an external review through the North Carolina Department of Insurance, which assigns an independent review organization (IRO) to evaluate the case. The IRO's decision is binding on BCBSNC.

Throughout this process, many patients can access a short-term supply. North Carolina pharmacy law permits a 72-hour emergency supply of maintenance medications when insurance issues delay coverage.

Eliquis Dosing and Monitoring Basics for BCBSNC Members

BCBSNC's quantity limits align with FDA-approved dosing. The standard dose for atrial fibrillation is 5 mg twice daily. A reduced dose of 2.5 mg twice daily is indicated for patients who meet at least two of three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher [10].

For DVT/PE treatment, the regimen starts at 10 mg twice daily for 7 days, then drops to 5 mg twice daily. Extended prophylaxis uses 2.5 mg twice daily after at least 6 months of full treatment.

Unlike warfarin, apixaban does not require routine blood monitoring. There is no INR target to chase. This eliminates the cost of regular lab visits and the clinical risk of over- or under-anticoagulation. A 2018 analysis in the Journal of the American Heart Association estimated that the total cost of warfarin management (including lab work, clinic visits, and adverse-event treatment) can approach or exceed the cost of a DOAC for many patients [11].

BCBSNC covers anti-factor Xa level testing when clinically indicated (e.g., before emergency surgery or in cases of suspected overdose), though this is rarely needed in routine care. Renal function should be assessed at baseline and at least annually, as apixaban is partially cleared by the kidneys (approximately 27% renal excretion) [10].

Switching Between Anticoagulants on a BCBSNC Plan

If you are currently on warfarin and your physician recommends switching to Eliquis, BCBSNC does not typically require you to "fail" warfarin first (unless your specific employer plan has a step-therapy protocol). The transition protocol is straightforward: discontinue warfarin, wait until the INR drops below 2.0, then start apixaban at the appropriate dose [10].

Switching from one DOAC to another (for example, rivaroxaban to apixaban) can be done at the time the next dose would have been due. No bridging with injectable anticoagulants is needed. Your BCBSNC plan will fill the new prescription as a standard formulary claim, though you should confirm tier placement if you are switching for cost reasons.

If your BCBSNC plan changes its formulary mid-year and moves Eliquis to a higher tier or removes it, you are entitled to a transition supply. Federal regulations for Medicare plans and North Carolina state rules for commercial plans require insurers to provide at least a 30-day bridge supply at the previous cost-sharing level while your prescriber arranges alternatives or submits an exception.